Findings seen through 76 weeks of treatment for adolescents taking 15- or 30-mg doses for moderate-to-severe atopic dermatitis<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Oct. 25, 2024 (HealthDay News) — Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA Dermatology<\/em>.<\/p>\n Amy S. Paller, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues evaluated the efficacy and adverse events of upadacitinib in adolescent patients with moderate-to-severe AD through 76 weeks. The analysis included data from 542 adolescents participating in the Measure Up 1, Measure Up 2, and AD Up clinical trials.<\/p>\n The researchers found that at week 76, \u226575 percent reduction in the Eczema Area and Severity Index Score (EASI-75) was achieved by 89.1, 84.4, and 87.8 percent of adolescents taking upadacitinib 15 mg in the Measure Up 1, Measure Up 2, and AD Up trials, respectively. For a dose of 30 mg, EASI-75 was achieved by 96.1, 93.6, and 82.7 percent of adolescents, respectively. Across both upadacitinib doses, results indicated maintenance or improvement of EASI-75 across 76 weeks. Long-term outcomes in trial participants were consistent with the known adverse event profile of upadacitinib (herpetic infection: 4.0, 1.9, and 1.1 events per 100 patient-years, respectively; creatine kinase elevation: 11.6, 11.0, and 7.1 events per 100 patient-years, respectively), with no new signals noted with either dose.<\/p>\n “While the difference in the proportions of patients achieving at least EASI-75 between the two upadacitinib treatment groups is small, the difference between the two doses becomes more pronounced over time in the more stringent efficacy end points, such as EASI-90,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures upadacitinib and funded the study.<\/p>\n